Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine
Lin Ru Koong, Wai Kitt Chee, Zhi Hong Toh, Xin Le Ng, Rupesh Agrawal, Su Ling Ho
Abstract
A 54-year-old Chinese male with no previous ocular history presented to the ophthalmology department for the bilateral acute painless blurring of vision after receiving the 1st dose of COVID-19 mRNA vaccine (PFIZER-BioNTech/COMIRNATY). Clinical examination and imaging tests were consistent with Vogt-Koyanagi-Hara disease. The patient responded well with a high dose of intravenous methylprednisolone followed by a tapering dose of oral prednisolone.
Topics & Concepts
MedicineVogt–Koyanagi–Harada diseaseMethylprednisolonePrednisoloneOphthalmologyCoronavirus disease 2019 (COVID-19)DermatologyDiseaseSurgeryUveitisInternal medicineInfectious disease (medical specialty)Ocular Diseases and Behçet’s SyndromeRetinal and Optic ConditionsOcular Infections and Treatments